Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.

Cannabinoid receptor 2 (CB(2) receptor) ligands are potential candidates for the therapy of chronic pain, inflammatory disorders, atherosclerosis, and osteoporosis. We describe the development of pharmacophore models for CB(2) receptor ligands, as well as a pharmacophore-based virtual screening workflow, which resulted in 14 hits for experimental follow-up. Seven compounds were identified with K(i) values below 25 microM. The CB(2) receptor-selective pyridine tetrahydrocannabinol analogue 8 (K(i) = 1.78 microM) was identified as a CB(2) partial agonist. Acetamides 12 (K(i) = 1.35 microM) and 18 (K(i) = 2.1 microM) represent new scaffolds for CB(2) receptor-selective antagonists and inverse agonists, respectively. Overall, our pharmacophore-based workflow yielded three novel scaffolds for the chemical development of CB(2) receptor ligands.

[1]  Xiang-Qun Xie,et al.  Beta-caryophyllene is a dietary cannabinoid , 2008, Proceedings of the National Academy of Sciences.

[2]  Y. Toda,et al.  Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. , 2008, Bioorganic & medicinal chemistry.

[3]  C. Lunn,et al.  Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists , 2008, British journal of pharmacology.

[4]  R. Pertwee.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. , 2008, British journal of pharmacology.

[5]  M. Cascio,et al.  New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. , 2007, Bioorganic & medicinal chemistry letters.

[6]  C. George,et al.  Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. , 2007, Journal of medicinal chemistry.

[7]  D. Pagé,et al.  New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists. , 2007, Bioorganic & medicinal chemistry letters.

[8]  V. Chapman,et al.  Cannabinoid CB2 Receptor-Mediated Anti-nociception in Models of Acute and Chronic Pain , 2007, Molecular Neurobiology.

[9]  B. Bingham,et al.  Species‐specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers , 2007, British journal of pharmacology.

[10]  Junmei Wang,et al.  GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..

[11]  François Durant,et al.  Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method. , 2006, European journal of medicinal chemistry.

[12]  P. C. White,et al.  Rimonabant: A novel CB1 receptor antagonist for the treatment of obesity , 2006 .

[13]  A. Vannacci,et al.  Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. , 2006, Journal of medicinal chemistry.

[14]  Thierry Langer,et al.  The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. , 2006, Journal of medicinal chemistry.

[15]  B. Martin,et al.  Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor. , 2006, Bioorganic & medicinal chemistry.

[16]  Tiziano Tuccinardi,et al.  Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. , 2006, Journal of medicinal chemistry.

[17]  Philippe Chavatte,et al.  Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. , 2006, Journal of medicinal chemistry.

[18]  Thierry Langer,et al.  Discovery of high-affinity ligands of σ1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening , 2005 .

[19]  J. Lange,et al.  Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. , 2005, Drug discovery today.

[20]  G. Hynd,et al.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. , 2005, Bioorganic & medicinal chemistry.

[21]  N. Campillo,et al.  Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. , 2005, European journal of medicinal chemistry.

[22]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[23]  Henrik Boström,et al.  Improving structure-based virtual screening by multivariate analysis of scoring data. , 2003, Journal of medicinal chemistry.

[24]  D. Diller,et al.  Kinases, homology models, and high throughput docking. , 2003, Journal of medicinal chemistry.

[25]  T. Vanderah,et al.  CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? , 2003, Current opinion in pharmacology.

[26]  Yong Wang,et al.  Design and synthesis of dipeptide nitriles as reversible and potent Cathepsin S inhibitors. , 2002, Journal of medicinal chemistry.

[27]  R. Razdan,et al.  Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[28]  R. Mechoulam,et al.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Casellas,et al.  SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. , 1999, The Journal of pharmacology and experimental therapeutics.

[30]  P. Prasit,et al.  NEW CLASS OF POTENT LIGANDS FOR THE HUMAN PERIPHERAL CANNABINOID RECEPTOR , 1996 .

[31]  D. Haycock,et al.  Putative aminoalkylindoles (AAI) antagonists. , 1990, NIDA research monograph.

[32]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.